Nuvectra (NVTR) 10-Q 8 Aug 17 2017 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Jul. 27, 2017
Document Information [Line Items]
Entity Registrant Name	Nuvectra Corp
Entity Central Index Key	1,648,893
Trading Symbol	nvtr
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		10,700,000
Document Type	10-Q
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unuadited) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 30, 2016
Current assets:
Cash and cash equivalents	$ 34,424	$ 63,710
Trade accounts receivable, net of allowance for doubtful accounts of $225 in fiscal 2017 and $10 in fiscal 2016	5,026	3,177
Inventories	3,542	5,233
Prepaid expenses and other current assets	1,136	443
Total current assets	44,128	72,563
Property, plant and equipment, net	6,338	6,317
Intangible assets, net	1,570	1,714
Goodwill	38,182	38,182
Other long-term assets	526	526
Total assets	90,744	119,302
Current liabilities:
Accounts payable	3,285	9,928
Accrued liabilities	2,853	3,355
Accrued compensation	3,977	2,757
Less current portion of long-term debt	1,500
Total current liabilities	11,615	16,040
Other long-term liabilities	1,209	940
Total long-term debt	12,529	13,744
Total liabilities	25,353	30,724
Commitments and contingencies (Note 8)
Stockholders’ equity:
Common stock, $0.001 par value, 100,000,000 shares authorized; 10,489,091 and 10,319,627 shares issued and outstanding in fiscal 2017 and fiscal 2016, respectively	10	10
Additional paid-in capital	122,977	121,806
Accumulated other comprehensive loss		(2)
Accumulated deficit	(57,596)	(33,236)
Total stockholders’ equity	65,391	88,578
Total liabilities and stockholders’ equity	$ 90,744	$ 119,302

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Current Period Unuadited) (Parentheticals) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 30, 2016
Trade accounts receivable, allowance for doubtful accounts	$ 225	$ 10
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	10,489,091	10,319,627
Common stock, shares outstanding (in shares)	10,489,091	10,319,627

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jul. 01, 2016	Jun. 30, 2017	Jul. 01, 2016
Product	$ 6,665	$ 1,890	$ 11,253	$ 3,441
Service	558	664	1,010	1,175
Total sales	7,223	2,554	12,263	4,616
Product	3,273	927	5,374	1,728
Service	266	336	576	590
Total cost of sales	3,539	1,263	5,950	2,318
Gross profit	3,684	1,291	6,313	2,298
Operating expenses:
Selling, general and administrative expenses	11,186	6,094	21,991	10,179
Research, development and engineering costs, net	3,221	3,447	7,594	6,983
Other operating expenses				469
Total operating expenses	14,407	9,541	29,585	17,631
Operating loss	(10,723)	(8,250)	(23,272)	(15,333)
Interest expense, net	398	464	768	523
Other expense, net	117	47	320	47
Loss before provision for income taxes	(11,238)	(8,761)	(24,360)	(15,903)
Provision for income taxes
Net loss	(11,238)	(8,761)	(24,360)	(15,903)
Other comprehensive gain:
Unrealized holding gain on investments arising during period	2		2
Other comprehensive gain	2		2
Comprehensive loss	$ (11,236)	$ (8,761)	$ (24,358)	$ (15,903)
Basic and diluted net loss per share (in dollars per share)	$ (1.07)	$ (0.85)	$ (2.34)	$ (1.55)
Basic and diluted weighted average shares outstanding (in shares)	10,458	10,266	10,396	10,262

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2017	Jul. 01, 2016
Cash flows from operating activities:
Net loss	$ (24,360,000)	$ (15,903,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Provision for uncollectible accounts	215,000
Writedowns of excess and obsolete inventories	203,000
Depreciation and amortization	755,000	938,000
Debt related amortization included in interest expense	327,000	188,000
Stock-based compensation	1,105,000	1,251,000
Loss on disposal of property, plant and equipment		21,000
Changes in operating assets and liabilities:
Trade accounts receivable	(2,064,000)	(1,607,000)
Inventories	1,488,000	(836,000)
Prepaid expenses and other current assets	(693,000)	(608,000)
Other long-term assets		(526,000)
Accounts payable and other current liabilities	(7,161,000)	7,602,000
Accrued compensation	1,220,000	831,000
Other long-term liabilities	269,000	657,000
Net cash used in operating activities	(28,696,000)	(7,992,000)
Cash flows from investing activities:
Acquisition of property, plant and equipment	(614,000)	(1,819,000)
Net cash used in investing activities	(614,000)	(1,819,000)
Cash flows from financing activities:
Borrowings under credit facility		15,000,000
Purchase of non-controlling interests		(6,818,000)
Net funding and capital contribution provided by Integer		86,421,000
Proceeds from the exercise of stock options	66,000	59,000
Payment of debt issuance costs	(42,000)	(1,528,000)
Net cash provided by financing activities	24,000	93,134,000
Net (decrease) increase in cash and cash equivalents	(29,286,000)	83,323,000
Cash and cash equivalents, beginning of period	63,710,000	202,000
Cash and cash equivalents, end of period	34,424,000	83,525,000
Supplemental Disclosure of Cash Flow Information:
Acquisition of property, plant and equipment accrued not paid	$ 18,000	$ 100,000

Condensed Consolidated Stateme6

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - 6 months ended Jun. 30, 2017 - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Dec. 30, 2016	10,320,000
Balance at Dec. 30, 2016	$ 10	$ 121,806	$ (33,236)	$ (2)	$ 88,578
Option exercises (in shares)	15,000				16,007
Option exercises		66			$ 66
Restricted stock issued, net of stock forfeited (in shares)	154,000
Restricted stock issued, net of stock forfeited
Stock-based compensation		1,105			1,105
Unrealized holding period gain				2	2
Net loss			(24,360)		(24,360)
Balance at Jun. 30, 2017	$ 10	$ 122,977	$ (57,596)		$ 65,391
Balance (in shares) at Jun. 30, 2017	10,489,000

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Significant Accounting Policies [Text Block]	1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of Operations Nuvectra Corporation, together with its wholly-owned subsidiaries (i) Algostim, LLC (“Algostim”), (ii) PelviStim LLC (“PelviStim”), and (iii) NeuroNexus Technologies, Inc. (“NeuroNexus”) (collectively “Nuvectra” or the “Company”), is a neurostimulation company committed to helping physicians improve the lives of people with chronic neurological conditions. The Algovita® Spinal Cord Stimulation (“SCS”) System (“Algovita”) is the Company’s first On March 14, 2016 Basis of Presentation 270, Interim Reporting 10 10 X. not not may Liquidity and Capital Resources Company has incurred significant net losses and negative cash flows from operations since inception and expects to incur additional net losses for the foreseeable future. Immediately prior to completion of the Spin-off, Integer made a cash capital contribution to Nuvectra of $75 $25 six twelve six no may may not may may no financing. Fiscal Year End 2017, fifty fifty-three December 31. second first six 2016 13 26 July 1, 2016 December 30, 2016. 2017, Use of Estimates Inventories first first not $0.05 $0 second 2017 2016, may Impairment of Long-Lived Assets may not not, not 50 Potential recoverability is measured by comparing the carrying amount of the asset or asset group to its related total future undiscounted cash flows. The projected cash flows for each asset or asset group considers multiple factors, including current revenue from existing customers, proceeds from the sale of the asset or asset group and expected profit margins giving consideration to historical and expected margins. If the carrying value is not no Goodwill Valuation may not first December 30, 2016, first two first 4.5% 34.1% June 30, 2017 not Warranty Reserve Revenue Recognition not Service revenue is recognized as the services are performed. The Company’s development services are typically provided on a fixed-fee basis. The revenues for such longer duration projects are typically recognized using the proportional performance method. In using the proportional performance method, revenues are generally recorded based on the percentage of effort incurred to date on a contract relative to the estimated total expected contract effort. Estimating total contract effort and progress to completion on the arrangements, as well as whether a loss is expected to be incurred on the contract, requires significant judgment. Management uses historical experience, project plans and an assessment of the risks and uncertainties inherent in the arrangements to establish these estimates. Various uncertainties may may not Deferred revenue consists primarily of service revenue not Subsequent Events

Note 2 - Intangible Assets

Note 2 - Intangible Assets	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	2. INTANGIBLE ASSETS Intangible assets are comprised of the following (in thousands): Gross Carrying Amount Accumulated Amortization Net Carrying Amount At June 30, 2017 Technology and patents $ 1,058 $ (561 ) $ 497 Customer lists 1,869 (796 ) 1,073 Total intangible assets $ 2,927 $ (1,357 ) $ 1,570 At December 30, 2016 Technology and patents $ 1,058 $ (498 ) $ 560 Customer lists 1,869 (715 ) 1,154 Total intangible assets $ 2,927 $ (1,213 ) $ 1,714 Aggregate intangible asset amortization expense is classified as follows (in thousands): Three Months Ended Six Months Ended June 30, 2017 July 1, 2016 June 30, 2017 July 1, 2016 Cost of sales $ 31 $ 27 $ 63 $ 55 Selling, general and administrative expenses 41 40 81 80 Total intangible asset amortization expense $ 72 $ 67 $ 144 $ 135 Estimated future intangible asset amortization expense based on the current carrying value is as follows (in thousands): Estimated Amortization Expense Remainder of 2017 $ 142 2018 298 2019 293 2020 209 2021 194 Thereafter 434 Total estimated amortization expense $ 1,570

Note 3 - Accrued Liabilities

Note 3 - Accrued Liabilities	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	3. Accrued Liabilities Accrued liabilities consisted of the following (in thousands): At June 30, 2017 December 30, 2016 Research and development $ 547 $ 165 Inventory 408 547 Regulatory, clinical and quality 405 640 Operations engagement fee 200 600 Sales and marketing 164 — Warranty reserve 154 98 Deferred revenue 148 — Legal 125 98 Information technology system and infrastructure implementations 120 327 Interest 102 99 Sales and use tax 55 56 Travel and entertainment — 285 Accrued other 425 440 Total accrued liabilities $ 2,853 $ 3,355

Note 4 - Employee Benefit Plans

Note 4 - Employee Benefit Plans	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	4. EMPLOYEE BENEFIT PLANS Nuvectra Corporation 2016 2016 “2016 March 14, 2016. 2016 may may 2016 2016 2,362,785. During the six June 30, 2017, 538,502 2016 2016 three six June 30, 2017 $0.5 $0.9 During the six July 1, 2016, 791,238 2016 2016 three six July 1, 2016 $0.4 $0.4 Stock-Based Compensation three $0.1 $0.2 three six June 30, 2017, $0.1 $0.8 three six July 1, 2016, The components and classification of stock-based compensation expense were as follows (in thousands): Three Months Ended Six Months Ended June 30, 2017 July 1, 2016 June 30, 2017 July 1, 2016 Stock options $ 239 $ 185 $ 410 $ 248 Restricted stock and restricted stock units 389 360 695 1,003 Total stock-based compensation expense $ 628 $ 545 $ 1,105 $ 1,251 Three Months Ended Six Months Ended June 30, 2017 July 1, 2016 June 30, 2017 July 1, 2016 Selling, general and administrative expense $ 542 $ 453 $ 984 $ 619 Research, development and engineering costs, net 86 92 121 163 Other operating expenses — — — 469 Total stock-based compensation expense $ 628 $ 545 $ 1,105 $ 1,251 The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model with weighted-average assumptions based on the grant date. The weighted average fair value and assumptions used to value options granted under the 2016 Three Months Ended Six Months Ended June 30, 2017 July 1, 2016 June 30, 2017 July 1, 2016 Weighted average fair value $ 3.61 $ 4.50 $ 3.57 $ 4.50 Risk-free interest rate 2.04 % 1.72 % 2.06 % 1.72 % Expected volatility 55 % 55 % 55 % 55 % Holding period (in years) 6 10 6 10 Expected dividend yield — % — % — % — % The following table summarizes the stock option activity during the first six 2017: Number of Time-Vested Stock Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding at December 30, 2016 873,992 $ 6.49 Granted 332,469 6.74 Exercised (16,007 ) 4.91 Forfeited or expired (28,880 ) 7.79 Outstanding at June 30, 2017 1,161,574 $ 6.55 6.52 $ 7,813,773 Exercisable at June 30, 2017 616,615 $ 6.14 4.02 $ 4,399,729 The Company received proceeds totaling $66,000 16,007 first six 2017. The following table summarizes the restricted stock and restricted stock unit activity during the first six 2017: Time-Vested Activity Weighted Average Fair Value Nonvested at December 30, 2016 551,224 $ 6.90 Granted 206,033 6.67 Vested (146,754 ) 6.47 Forfeited (73,353 ) 6.47 Nonvested at June 30, 2017 537,150 $ 6.86 Nuvectra Bonus Plan three six June 30, 2017 $0.6 $1.3 three six July 1, 2016 $0.3 $1.0 Defined Contribution Plans 401 401 1986, 401 three six June 30, 2017 25% 6% $0.07 $0.1 three six June 30, 2017, Integer sponsors a defined contribution 401 401 first 2016 35% 6% 401 first 2016 condensed consolidated financial statements includes all of the compensation expenses directly attributable to Nuvectra employees. Direct costs related to this defined contribution plan allocated to the Company were $0.03 $0.07 three six July 1, 2016,

Note 5 - Other Operating Expens

Note 5 - Other Operating Expenses	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Other Operating Income and Expense [Text Block]	5. OTHER OPERATING EXPENSES Performance Restricted Stock Expense 2015 no $469,000 March 14, 2016

Note 6 - Debt

Note 6 - Debt	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Debt Disclosure [Text Block]	6. DEBT Long-term debt is comprised of the following (in thousands): At June 30, 2017 December 30, 2016 Term loan $ 16,163 $ 16,163 Deferred financing fees (1,131 ) (1,262 ) Discount on debt (1,003 ) (1,157 ) Total debt 14,029 13,744 Less current portion of long-term debt 1,500 — Total long-term debt $ 12,529 $ 13,744 Credit Facility February 2017 ( $40,000,000 $15,000,000 March 18, 2016, ( $12,500,000 June 30, 2017 December 31, 2017, $12,500,000 December 31, 2017 June 30, 2018 ( $5,000,000 six $13,500,000, six $20,000,000. Based on the Company’s sequential quarterly revenue growth since the commercial release of its Algovita system into the United States market, and on its expectations of future and continued revenue growth, the Company believes that it should be able to achieve these consolidated trailing six no may The Company has the right to draw on the Term Loan B and C Commitments within 60 80% may The Term Loans bear interest at a floating rate equal to the prime rate plus 4.15%, 7.65%. June 30, 2017 8.15%. December 2017 ( March 2018 33 30 September 1, 2020, 7.75% 3.45%, 6.95%. March 18, 2018, no June 30, 2017. On March 18, 2016 $1,125,000 2.50% $200,000 one $25,000 one one February 14, 2017, $25,000 2% 3% first 2% second 1% The Loans are secured by a first The Credit Facility contains customary representations and warranties, reporting and other covenants for credit facilities of this kind including prohibitions on the payment of cash dividends on the Company’s capital stock and restrictions on mergers, sales of assets, investments, incurrence of liens, incurrence of indebtedness and transactions with affiliates. If the lenders fund the Term Loan B Commitment, the Company will be subject to a quarterly financial covenant requiring the Company to achieve consolidated revenues of at least 75% As a condition to the lenders’ funding the Loans under the Credit Facility, concurrently with the funding under the Term Loan A Commitment on March 18, 2016, ( 56,533 $5.97 March 18, 2026, 56,533 $5.97 March 18, 2026. $0.2 Upon the funding of each of the Term Loan B Commitment and the Term Loan C Commitment, as applicable, Oxford Finance LLC and Silicon Valley Bank will each be entitled to additional warrants for the purchase of Nuvectra common stock. The number of shares under each warrant will be equal to the amount of the Term Loan made by each lender multiplied by 4.50% June 30, 2017 $0.6 not 10 Deferred Financing Fees – At December 30, 2016 $ 1,262 Additions during the period 42 Amortization during the period (173 ) At June 30, 2017 $ 1,131 In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2015 03, 835 30

Note 7 - Income Taxes

Note 7 - Income Taxes	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Income Tax Disclosure [Text Block]	7. INCOME TAXES The income tax provision for interim periods is determined using an estimate of the annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to several factors, including changes in the mix of the pre-tax income and the jurisdictions to which it relates, changes in tax laws, business reorganizations and settlements with taxing authorities. The Company records a valuation allowance when it is “more likely than not” not Pursuant to the terms of the tax matters agreement entered into with Integer at the time of the Spin-off, until March 14, 2018, one 30% 35% may

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	8. COMMITMENTS AND CONTINGENCIES Litigation – not no not Purchase Commitments As of June 30, 2017, $9.3 June 30, 2017, no 2017 $1.6 The Company’s significant long-term obligations are operating leases on its facilities.

Note 9 - Earnings (Loss) Per Sh

Note 9 - Earnings (Loss) Per Share ("EPS")	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Earnings Per Share [Text Block]	9. EARNINGS (LOSS) PER SHARE (“EPS”) Basic net loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is equal to basic net loss per share as the Company had no The following table illustrates the calculation of Basic and Diluted EPS (in thousands, except per share amounts): Three Months Ended Six Months Ended June 30, 2017 July 1, 2016 June 30, 2017 July 1, 2016 Basic net loss per share: Net loss $ (11,238 ) $ (8,761 ) $ (24,360 ) $ (15,903 ) Weighted average common shares outstanding 10,458 10,266 10,396 10,262 Basic net loss per share $ (1.07 ) $ (0.85 ) $ (2.34 ) $ (1.55 ) Diluted net loss per share: Net loss $ (11,238 ) $ (8,761 ) $ (24,360 ) $ (15,903 ) Weighted average common shares outstanding 10,458 10,266 10,396 10,262 Dilutive stock options, restricted stock and restricted stock units — — — — Weighted average common shares outstanding – assuming dilution 10,458 10,266 10,396 10,262 Diluted net loss per share $ (1.07 ) $ (0.85 ) $ (2.34 ) $ (1.55 ) Outstanding securities and warrants that were not included in the diluted calculation because their effect would be anti-dilutive 1,812 1,652 1,812 1,652

Note 10 - Fair Value Measuremen

Note 10 - Fair Value Measurements	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Fair Value Disclosures [Text Block]	10. FAIR VALUE MEASUREMENTS The carrying amounts of cash, accounts receivable, accounts payable, and accrued expenses approximate fair value because of the short-term nature of these items. As of June 30, 2017, 2 Assets and Liabilities Measured at Fair Value on a Recurring Basis Fair value measurement standards apply to certain financial assets and liabilities that are measured at fair value on a recurring basis (each reporting period). The Company has categorized its warrants measured at fair value on a recurring basis in Level 3 $0.5 six June 30, 2017, $0.3 June 30, 2017 $0.6 The Company’s investments in marketable securities primarily consist of investments in debt securities, which are classified as available-for-sale and presented as current assets within Cash and Cash Equivalents on the balance sheet because of their original maturities of three The fair values of marketable securities were estimated using the market approach using prices and other relevant information generated by market transactions involving identical or comparable assets. The Company uses quoted market prices in active markets or quoted market prices in markets that are not June 30, 2017, $30.2 three Marketable securities, measured at fair value, by level within the fair value hierarchy were as follows (in thousands): June 30, 2017 Fair Value Hierarchy Cost Unrealized Loss Fair Value Cash Level 1 $ 16,665 $ — $ 16,665 Agency Level 1 4,495 — 4,495 Financial Level 2 5,993 — 5,993 Industrial Level 2 2,999 — 2,999 Total $ 30,152 $ — $ 30,152 December 30, 2016 Fair Value Hierarchy Cost Unrealized Loss Fair Value Cash Level 1 $ 33,821 $ — $ 33,821 Government Level 1 2,005 — 2,005 Financial Level 2 8,064 (1 ) 8,063 Industrial Level 2 11,125 (1 ) 11,124 Total $ 55,015 $ (2 ) $ 55,013 Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis Fair value standards also apply to certain assets and liabilities that are measured at fair value on a nonrecurring basis. A summary of the valuation methodologies for assets and liabilities measured on a nonrecurring basis is as follows: Long-lived Assets 1 Goodwill not 1 second first six 2017 2016, no Warrants 10 March 18, 2016. The following table summarizes the assumptions as of June 30, 2017 Risk-free interest rate 2.16 % Expected volatility 55.00 % Contractual term (in years) 10 Dividend yield — %

Note 11 - Business Segment, Geo

Note 11 - Business Segment, Geographic and Concentration Risk Information	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Segment Reporting, Geographical, and Concentration Risk Disclosure [Text Block]	11. BUSINESS SEGMENT, GEOGRAPHIC AND CONCENTRATION RISK INFORMATION As a new public entity, the Company commenced its first fourth 2016. two two Nuvectra is a neurostimulation company committed to helping physicians improve the lives of people with chronic neurological conditions. Algovita is the Company’s first TM , the second first NeuroNexus designs, manufactures and markets neural-interface technologies for the neuroscience clinical research market. Revenue includes sales of neural interface technology, components and systems to the neuroscience and clinical markets. An analysis and reconciliation of the Company’s product lines, business segments and geographic information to the respective information in the Condensed Consolidated Financial Statements follows. Sales by geographic area are presented by allocating sales from external customers based on where the products are shipped or services are rendered (in thousands): Three Months Ended Six Months Ended June 30, 2017 July 1, 2016 June 30, 2017 July 1, 2016 Product line sales: Algovita $ 5,491 $ 569 $ 8,878 $ 984 Neural interface components and systems 1,174 1,321 2,375 2,457 Development and engineering service 558 664 1,010 1,175 Total sales $ 7,223 $ 2,554 $ 12,263 $ 4,616 Three Months Ended Six Months Ended June 30, 2017 July 1, 2016 June 30, 2017 July 1, 2016 Business segment sales: Nuvectra $ 6,049 $ 1,233 $ 9,888 $ 2,159 NeuroNexus 1,174 1,321 2,375 2,457 Total sales $ 7,223 $ 2,554 $ 12,263 $ 4,616 Three Months Ended Six Months Ended June 30, 2017 July 1, 2016 June 30, 2017 July 1, 2016 Segment (loss) income from operations: Nuvectra $ (10,813 ) $ (8,316 ) $ (23,418 ) $ (15,217 ) NeuroNexus 90 66 146 (116 ) Total segment (loss) income from operations (10,723 ) (8,250 ) (23,272 ) (15,333 ) Unallocated operating expenses — — — — Operating loss (10,723 ) (8,250 ) (23,272 ) (15,333 ) Unallocated other expense, net (515 ) (511 ) (1,088 ) (570 ) Loss before provision for income taxes $ (11,238 ) $ (8,761 ) $ (24,360 ) $ (15,903 ) Three Months Ended Six Months Ended June 30, 2017 July 1, 2016 June 30, 2017 July 1, 2016 Sales by geographic area: United States $ 5,601 $ 1,163 $ 9,371 $ 1,827 Non-Domestic locations: Switzerland 586 724 1,059 1,270 Germany 523 309 874 865 Rest of world 513 358 959 654 Total sales $ 7,223 $ 2,554 $ 12,263 $ 4,616 All of the Company’s long-lived tangible assets are located in the United States.

Note 12 - Related Party Transac

Note 12 - Related Party Transactions	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	12. related party transactions On March 14, 2016 $75.0 Employee Benefit Plans 4 Supply Agreement

Note 13 - Recently Issued Accou

Note 13 - Recently Issued Accounting Standards	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	13. RECENTLY ISSUED ACCOUNTING STANDARDS In the normal course of business, management evaluates all new accounting pronouncements issued by the FASB to determine the potential impact they may not not Recently Adopted In January 2017, 2017 04, 350 two not December 15, 2019. January 1, 2017. 2017 04 In March 2016, 2016 09, 718, 2016 09 first 2017 no no no not 2016 09 not In July 2015, 2015 11, 330 not first first 2017. 2015 11 not Condensed Consolidated Financial Statements. Not In May 2017, 2017 09, 718 2017 09 2017 09, not 2017 09 December 15, 2017. 2017 09 2018. not 2017 09 Condensed Consolidated Financial Statements. In January 2017, 2017 01, 805 2017 01 not not not 2017 01 December 15, 2017, first 2018 not 2017 01 Condensed Consolidated Financial Statements. In August 2016, 2016 15, 230 2016 15 eight December 15, 2017, first 2018 not 2016 15 Condensed Consolidated Financial Statements. In February 2016, 2016 02, 2016 02 2016 02 December 15, 2018 ( Condensed Consolidated Financial Statements. In January 2016, 2016 01, December 15, 2017, not Condensed Consolidated Financial Statements. In May 2014, 2014 09, 2014 09 five two August 2015, 2015 14 2014 09 December 15, 2017, December 15, 2016. March 2016, 2016 08, 606 2014 09. April 2016, 2016 10, 606 2014 9. May 2016, 2016 11, 605 815 2014 09 2014 16 March 3, 2016 2016 11 two March 3, 2016 2016 11 605 December 15, 2017 815 December 15, 2015. May 2016, 2016 12, 606 2014 9. January 1, 2018 third 2017. third 2017 January 1, 2018.

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Nature of Operations [Policy Text Block]	Nature of Operations Nuvectra Corporation, together with its wholly-owned subsidiaries (i) Algostim, LLC (“Algostim”), (ii) PelviStim LLC (“PelviStim”), and (iii) NeuroNexus Technologies, Inc. (“NeuroNexus”) (collectively “Nuvectra” or the “Company”), is a neurostimulation company committed to helping physicians improve the lives of people with chronic neurological conditions. The Algovita® Spinal Cord Stimulation (“SCS”) System (“Algovita”) is the Company’s first On March 14, 2016
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation 270, Interim Reporting 10 10 X. not not may
Liquidity and Capital Resources [Policy Text Block]	Liquidity and Capital Resources Company has incurred significant net losses and negative cash flows from operations since inception and expects to incur additional net losses for the foreseeable future. Immediately prior to completion of the Spin-off, Integer made a cash capital contribution to Nuvectra of $75 $25 six twelve six no may may not may may no financing.
Fiscal Period, Policy [Policy Text Block]	Fiscal Year End 2017, fifty fifty-three December 31. second first six 2016 13 26 July 1, 2016 December 30, 2016. 2017,
Use of Estimates, Policy [Policy Text Block]	Use of Estimates
Inventory, Policy [Policy Text Block]	Inventories first first not $0.05 $0 second 2017 2016, may
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets may not not, not 50 Potential recoverability is measured by comparing the carrying amount of the asset or asset group to its related total future undiscounted cash flows. The projected cash flows for each asset or asset group considers multiple factors, including current revenue from existing customers, proceeds from the sale of the asset or asset group and expected profit margins giving consideration to historical and expected margins. If the carrying value is not no
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill Valuation may not first December 30, 2016, first two first 4.5% 34.1% June 30, 2017 not
Standard Product Warranty, Policy [Policy Text Block]	Warranty Reserve
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition not Service revenue is recognized as the services are performed. The Company’s development services are typically provided on a fixed-fee basis. The revenues for such longer duration projects are typically recognized using the proportional performance method. In using the proportional performance method, revenues are generally recorded based on the percentage of effort incurred to date on a contract relative to the estimated total expected contract effort. Estimating total contract effort and progress to completion on the arrangements, as well as whether a loss is expected to be incurred on the contract, requires significant judgment. Management uses historical experience, project plans and an assessment of the risks and uncertainties inherent in the arrangements to establish these estimates. Various uncertainties may may not Deferred revenue consists primarily of service revenue not
Subsequent Events, Policy [Policy Text Block]	Subsequent Events

Note 2 - Intangible Assets (Tab

Note 2 - Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Gross Carrying Amount Accumulated Amortization Net Carrying Amount At June 30, 2017 Technology and patents $ 1,058 $ (561 ) $ 497 Customer lists 1,869 (796 ) 1,073 Total intangible assets $ 2,927 $ (1,357 ) $ 1,570 At December 30, 2016 Technology and patents $ 1,058 $ (498 ) $ 560 Customer lists 1,869 (715 ) 1,154 Total intangible assets $ 2,927 $ (1,213 ) $ 1,714
Finite-lived Intangible Assets Amortization Expense [Table Text Block]	Three Months Ended Six Months Ended June 30, 2017 July 1, 2016 June 30, 2017 July 1, 2016 Cost of sales $ 31 $ 27 $ 63 $ 55 Selling, general and administrative expenses 41 40 81 80 Total intangible asset amortization expense $ 72 $ 67 $ 144 $ 135
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Estimated Amortization Expense Remainder of 2017 $ 142 2018 298 2019 293 2020 209 2021 194 Thereafter 434 Total estimated amortization expense $ 1,570

Note 3 - Accrued Liabilities (T

Note 3 - Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	At June 30, 2017 December 30, 2016 Research and development $ 547 $ 165 Inventory 408 547 Regulatory, clinical and quality 405 640 Operations engagement fee 200 600 Sales and marketing 164 — Warranty reserve 154 98 Deferred revenue 148 — Legal 125 98 Information technology system and infrastructure implementations 120 327 Interest 102 99 Sales and use tax 55 56 Travel and entertainment — 285 Accrued other 425 440 Total accrued liabilities $ 2,853 $ 3,355

Note 4 - Employee Benefit Pla23

Note 4 - Employee Benefit Plans (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]	Three Months Ended Six Months Ended June 30, 2017 July 1, 2016 June 30, 2017 July 1, 2016 Stock options $ 239 $ 185 $ 410 $ 248 Restricted stock and restricted stock units 389 360 695 1,003 Total stock-based compensation expense $ 628 $ 545 $ 1,105 $ 1,251 Three Months Ended Six Months Ended June 30, 2017 July 1, 2016 June 30, 2017 July 1, 2016 Selling, general and administrative expense $ 542 $ 453 $ 984 $ 619 Research, development and engineering costs, net 86 92 121 163 Other operating expenses — — — 469 Total stock-based compensation expense $ 628 $ 545 $ 1,105 $ 1,251
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three Months Ended Six Months Ended June 30, 2017 July 1, 2016 June 30, 2017 July 1, 2016 Weighted average fair value $ 3.61 $ 4.50 $ 3.57 $ 4.50 Risk-free interest rate 2.04 % 1.72 % 2.06 % 1.72 % Expected volatility 55 % 55 % 55 % 55 % Holding period (in years) 6 10 6 10 Expected dividend yield — % — % — % — %
Restricted Stock and RSU's [Member]
Notes Tables
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	Time-Vested Activity Weighted Average Fair Value Nonvested at December 30, 2016 551,224 $ 6.90 Granted 206,033 6.67 Vested (146,754 ) 6.47 Forfeited (73,353 ) 6.47 Nonvested at June 30, 2017 537,150 $ 6.86
Employee Stock Option [Member]
Notes Tables
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	Number of Time-Vested Stock Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding at December 30, 2016 873,992 $ 6.49 Granted 332,469 6.74 Exercised (16,007 ) 4.91 Forfeited or expired (28,880 ) 7.79 Outstanding at June 30, 2017 1,161,574 $ 6.55 6.52 $ 7,813,773 Exercisable at June 30, 2017 616,615 $ 6.14 4.02 $ 4,399,729

Note 6 - Debt (Tables)

Note 6 - Debt (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Long-term Debt Instruments [Table Text Block]	At June 30, 2017 December 30, 2016 Term loan $ 16,163 $ 16,163 Deferred financing fees (1,131 ) (1,262 ) Discount on debt (1,003 ) (1,157 ) Total debt 14,029 13,744 Less current portion of long-term debt 1,500 — Total long-term debt $ 12,529 $ 13,744
Schedule of Debt Issuance Costs [Table Text Block]	At December 30, 2016 $ 1,262 Additions during the period 42 Amortization during the period (173 ) At June 30, 2017 $ 1,131

Note 9 - Earnings (Loss) Per 25

Note 9 - Earnings (Loss) Per Share ("EPS") (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended Six Months Ended June 30, 2017 July 1, 2016 June 30, 2017 July 1, 2016 Basic net loss per share: Net loss $ (11,238 ) $ (8,761 ) $ (24,360 ) $ (15,903 ) Weighted average common shares outstanding 10,458 10,266 10,396 10,262 Basic net loss per share $ (1.07 ) $ (0.85 ) $ (2.34 ) $ (1.55 ) Diluted net loss per share: Net loss $ (11,238 ) $ (8,761 ) $ (24,360 ) $ (15,903 ) Weighted average common shares outstanding 10,458 10,266 10,396 10,262 Dilutive stock options, restricted stock and restricted stock units — — — — Weighted average common shares outstanding – assuming dilution 10,458 10,266 10,396 10,262 Diluted net loss per share $ (1.07 ) $ (0.85 ) $ (2.34 ) $ (1.55 ) Outstanding securities and warrants that were not included in the diluted calculation because their effect would be anti-dilutive 1,812 1,652 1,812 1,652

Note 10 - Fair Value Measurem26

Note 10 - Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	June 30, 2017 Fair Value Hierarchy Cost Unrealized Loss Fair Value Cash Level 1 $ 16,665 $ — $ 16,665 Agency Level 1 4,495 — 4,495 Financial Level 2 5,993 — 5,993 Industrial Level 2 2,999 — 2,999 Total $ 30,152 $ — $ 30,152 December 30, 2016 Fair Value Hierarchy Cost Unrealized Loss Fair Value Cash Level 1 $ 33,821 $ — $ 33,821 Government Level 1 2,005 — 2,005 Financial Level 2 8,064 (1 ) 8,063 Industrial Level 2 11,125 (1 ) 11,124 Total $ 55,015 $ (2 ) $ 55,013
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	Risk-free interest rate 2.16 % Expected volatility 55.00 % Contractual term (in years) 10 Dividend yield — %

Note 11 - Business Segment, G27

Note 11 - Business Segment, Geographic and Concentration Risk Information (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Revenue from External Customers by Products and Services [Table Text Block]	Three Months Ended Six Months Ended June 30, 2017 July 1, 2016 June 30, 2017 July 1, 2016 Product line sales: Algovita $ 5,491 $ 569 $ 8,878 $ 984 Neural interface components and systems 1,174 1,321 2,375 2,457 Development and engineering service 558 664 1,010 1,175 Total sales $ 7,223 $ 2,554 $ 12,263 $ 4,616
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Three Months Ended Six Months Ended June 30, 2017 July 1, 2016 June 30, 2017 July 1, 2016 Business segment sales: Nuvectra $ 6,049 $ 1,233 $ 9,888 $ 2,159 NeuroNexus 1,174 1,321 2,375 2,457 Total sales $ 7,223 $ 2,554 $ 12,263 $ 4,616 Three Months Ended Six Months Ended June 30, 2017 July 1, 2016 June 30, 2017 July 1, 2016 Segment (loss) income from operations: Nuvectra $ (10,813 ) $ (8,316 ) $ (23,418 ) $ (15,217 ) NeuroNexus 90 66 146 (116 ) Total segment (loss) income from operations (10,723 ) (8,250 ) (23,272 ) (15,333 ) Unallocated operating expenses — — — — Operating loss (10,723 ) (8,250 ) (23,272 ) (15,333 ) Unallocated other expense, net (515 ) (511 ) (1,088 ) (570 ) Loss before provision for income taxes $ (11,238 ) $ (8,761 ) $ (24,360 ) $ (15,903 )
Revenue from External Customers by Geographic Areas [Table Text Block]	Three Months Ended Six Months Ended June 30, 2017 July 1, 2016 June 30, 2017 July 1, 2016 Sales by geographic area: United States $ 5,601 $ 1,163 $ 9,371 $ 1,827 Non-Domestic locations: Switzerland 586 724 1,059 1,270 Germany 523 309 874 865 Rest of world 513 358 959 654 Total sales $ 7,223 $ 2,554 $ 12,263 $ 4,616

Note 1 - Summary of Significa28

Note 1 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	Mar. 14, 2016	Feb. 28, 2017	Jun. 30, 2017	Jul. 01, 2016	Jun. 30, 2017	Jul. 01, 2016	Dec. 30, 2016
Proceeds from Contributions from Former Parent						$ 86,421,000
Line of Credit, Portion Subject to Certain Revenue Milestones		$ 25,000,000
Inventory Write-down			$ 50,000	$ 0	$ 203,000
Nuvectra Segment [Member]
Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount							4.50%
NeuroNexus Segment [Member]
Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount							34.10%
Integer [Member]
Proceeds from Contributions from Former Parent	$ 75,000,000

Note 2 - Intangible Assets - Am

Note 2 - Intangible Assets - Amortizing Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 30, 2016
Gross carrying amount	$ 2,927	$ 2,927
Accumulated amortization	(1,357)	(1,213)
Net carrying amount	1,570	1,714
Patented Technology [Member]
Gross carrying amount	1,058	1,058
Accumulated amortization	(561)	(498)
Net carrying amount	497	560
Customer Lists [Member]
Gross carrying amount	1,869	1,869
Accumulated amortization	(796)	(715)
Net carrying amount	$ 1,073	$ 1,154

Note 2 - Intangible Assets - Ag

Note 2 - Intangible Assets - Aggregate Intangible Asset Amortization Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jul. 01, 2016	Jun. 30, 2017	Jul. 01, 2016
Intangible asset amortization expense	$ 72	$ 67	$ 144	$ 135
Cost of Sales [Member]
Intangible asset amortization expense	31	27	63	55
Selling, General and Administrative Expenses [Member]
Intangible asset amortization expense	$ 41	$ 40	$ 81	$ 80

Note 2 - Intangible Assets - Fu

Note 2 - Intangible Assets - Future Intangible Asset Amortization Expense (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 30, 2016
Remainder of 2017	$ 142
2,018	298
2,019	293
2,020	209
2,021	194
Thereafter	434
Total estimated amortization expense	$ 1,570	$ 1,714

Note 3 - Accrued Liabilities -

Note 3 - Accrued Liabilities - Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 30, 2016
Research and development	$ 547	$ 165
Inventory	408	547
Regulatory, clinical and quality	405	640
Operations engagement fee	200	600
Sales and marketing	164
Warranty reserve	154	98
Deferred revenue	148
Legal	125	98
Information technology system and infrastructure implementations	120	327
Interest	102	99
Sales and use tax	55	56
Travel and entertainment		285
Accrued other	425	440
Total accrued liabilities	$ 2,853	$ 3,355

Note 4 - Employee Benefit Pla33

Note 4 - Employee Benefit Plans (Details Textual) - USD ($)	3 Months Ended			6 Months Ended
	Jun. 30, 2017	Jul. 01, 2016	Apr. 01, 2016	Jun. 30, 2017	Jul. 01, 2016
Proceeds from Stock Options Exercised				$ 66,000	$ 59,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period				16,007
Defined Contribution Plan [Member]
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	6.00%			6.00%
Defined Contribution Plan, Cost	$ 70,000			$ 100,000
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	25.00%			25.00%
Integer Sponsored Defined Contribution Plan [Member]
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent			6.00%
Defined Contribution Plan, Cost		$ 30,000			70,000
Defined Contribution Plan, Employer Matching Contribution, Percent of Match			35.00%
Bonus Plan [Member]
Deferred Compensation Arrangement with Individual, Compensation Expense	$ 600,000	300,000		$ 1,300,000	1,000,000
Nuvectra Corporation 2016 Equity Incentive Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance	2,362,785			2,362,785
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	$ 500,000	400,000		$ 900,000	$ 400,000
Nuvectra Corporation 2016 Equity Incentive Plan [Member] | Restricted Stock Units and Non-Qualified Stock Options [Member] | Directors, Certain Officers and Key Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options and Options, Grants in Period				538,502	791,238
Integer Equity Incentives Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				3 years
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	$ 100,000	$ 100,000		$ 200,000	$ 800,000

Note 4 - Employee Benefit Pla34

Note 4 - Employee Benefit Plans - Allocated Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jul. 01, 2016	Jun. 30, 2017	Jul. 01, 2016
Allocated share-based compensation expense	$ 628	$ 545	$ 1,105	$ 1,251
Selling, General and Administrative Expenses [Member]
Allocated share-based compensation expense	542	453	984	619
Research and Development Expense [Member]
Allocated share-based compensation expense	86	92	121	163
Other Operating Income (Expense) [Member]
Allocated share-based compensation expense				469
Employee Stock Option [Member]
Allocated share-based compensation expense	239	185	410	248
Restricted Stock Units (RSUs) [Member]
Allocated share-based compensation expense	$ 389	$ 360	$ 695	$ 1,003

Note 4 - Employee Benefit Pla35

Note 4 - Employee Benefit Plans - Weighted Average Fair Value Assumption Used to Values Options Granted (Details) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jul. 01, 2016	Jun. 30, 2017	Jul. 01, 2016
Weighted average fair value (in dollars per share)	$ 3.61	$ 4.50	$ 3.57	$ 4.50
Risk-free interest rate	2.04%	1.72%	2.06%	1.72%
Expected volatility	55.00%	55.00%	55.00%	55.00%
Holding period (in years) (Year)	6 years	10 years	6 years	10 years
Expected dividend yield	0.00%

Note 4 - Employee Benefit Pla36

Note 4 - Employee Benefit Plans - Summary of Stock Option Activity (Details)	6 Months Ended
	Jun. 30, 2017USD ($)$ / sharesshares
Exercised, number of options (in shares)	(16,007)
Employee Stock Option [Member]
Outstanding, number of options (in shares)	873,992
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 6.49
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 6.55
Outstanding, weighted average remaining contractual life (Year)	6 years 189 days
Outstanding, aggregate intrinsic value | $	$ 7,813,773
Exercisable, number of options (in shares)	616,615
Exercisable, weighted average exercise price (in dollars per share) | $ / shares	$ 6.14
Granted, number of options (in shares)	332,469
Granted, weighted average exercise price (in dollars per share) | $ / shares	$ 6.74
Exercised, number of options (in shares)	(16,007)
Exercised, weighted average exercise price (in dollars per share) | $ / shares	$ 4.91
Forfeited or expired, number of options (in shares)	(28,880)
Forfeited or expired, weighted average exercise price (in dollars per share) | $ / shares	$ 7.79
Outstanding, number of options (in shares)	1,161,574
Exercisable, weighted average remaining contractual life (Year)	4 years 7 days
Exercisable, aggregate intrinsic value | $	$ 4,399,729

Note 4 - Employee Benefit Pla37

Note 4 - Employee Benefit Plans - Summary Restricted Stock Unit Activity (Details) - Restricted Stock and RSU's [Member]	6 Months Ended
	Jun. 30, 2017$ / sharesshares
Nonvested (in shares) | shares	551,224
Nonvested (in dollars per share) | $ / shares	$ 6.90
Nonvested (in dollars per share) | $ / shares	$ 6.86
Granted (in shares) | shares	206,033
Granted (in dollars per share) | $ / shares	$ 6.67
Vested (in shares) | shares	(146,754)
Vested (in dollars per share) | $ / shares	$ 6.47
Forfeited (in shares) | shares	(73,353)
Forfeited (in dollars per share) | $ / shares	$ 6.47
Nonvested (in shares) | shares	537,150

Note 5 - Other Operating Expe38

Note 5 - Other Operating Expenses (Details Textual)	Mar. 14, 2016USD ($)
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost	$ 469,000

Note 6 - Debt (Details Textual)

Note 6 - Debt (Details Textual) - USD ($)	Mar. 18, 2016	Jun. 30, 2017	Jul. 01, 2016	Feb. 14, 2017	Dec. 30, 2016
Long-term Debt		$ 14,029,000			$ 13,744,000
Payments of Debt Issuance Costs		42,000	$ 1,528,000
Additional Paid in Capital		122,977,000			$ 121,806,000
Derivative Liability		600,000
Warrant [Member]
Derivative Liability	$ 500,000	$ 600,000
Oxford Finance LLC and Silicon Valley Bank [Member] | Warrant [Member]
Additional Paid in Capital	200,000
Oxford Finance LLC and Silicon Valley Bank [Member] | Term Loan B Funded [Member]
Debt Covenant, Minimum Percentage of Forecasted Revenues Required		75.00%
Oxford Finance LLC and Silicon Valley Bank [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity		$ 5,000,000
Line of Credit Facility, Borrowing Base as Percentage of Accounts Receivable		80.00%
Debt Instrument, Interest Rate Floor		6.95%
Long-term Debt		$ 0
Line of Credit Facility, Commitment Fee Amount	25,000
Oxford Finance LLC and Silicon Valley Bank [Member] | Revolving Credit Facility [Member] | Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate		3.45%
Oxford Finance LLC and Silicon Valley Bank [Member] | Term Loans [Member] | Piper Jaffray [Member]
Payments of Debt Issuance Costs	$ 1,125,000
Debt Instrument, Arrangement Fee, Percentage	2.50%
Oxford Finance LLC and Silicon Valley Bank [Member] | Term Loans [Member]
Debt Agreement, Maximum Borrowing Capacity		$ 40,000,000
Debt Instrument, Interest Rate During Period		8.15%
Debt Instrument, Percentage of Funded Loan Amounts due at Maturity		7.75%
Debt Instrument, Interest Rate Floor		7.65%
Debt Instrument, Commitment Fee Amount	$ 200,000
Debt Instrument, Amendment Fee				$ 25,000
Oxford Finance LLC and Silicon Valley Bank [Member] | Term Loans [Member] | If Term Loan B Not Funded, Beginning January, 2018 [Member]
Debt Instrument, Number of Monthly Principal and Interest Payments		33
Oxford Finance LLC and Silicon Valley Bank [Member] | Term Loans [Member] | If Term Loan B Funded, Beginning April, 2018 [Member]
Debt Instrument, Number of Monthly Principal and Interest Payments		30
Oxford Finance LLC and Silicon Valley Bank [Member] | Term Loans [Member] | Prepayment in First Year After Initial Closing [Member]
Debt Instrument, Prepayment Fee Percentage		3.00%
Oxford Finance LLC and Silicon Valley Bank [Member] | Term Loans [Member] | Prepayment in Second Year After Initial Closing [Member]
Debt Instrument, Prepayment Fee Percentage		2.00%
Oxford Finance LLC and Silicon Valley Bank [Member] | Term Loans [Member] | Prepayment After Second Year After Initial Closing [Member]
Debt Instrument, Prepayment Fee Percentage		1.00%
Oxford Finance LLC and Silicon Valley Bank [Member] | Term Loans [Member] | Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate		4.15%
Oxford Finance LLC and Silicon Valley Bank [Member] | Term Loan A [Member]
Debt Agreement, Maximum Borrowing Capacity		$ 15,000,000
Oxford Finance LLC and Silicon Valley Bank [Member] | Term Loan B [Member]
Debt Agreement, Maximum Borrowing Capacity		12,500,000
Debt Covenant, Minimum Revenue Required for Trailing Six Months		13,500,000
Oxford Finance LLC and Silicon Valley Bank [Member] | Term Loan C [Member]
Debt Agreement, Maximum Borrowing Capacity		12,500,000
Debt Covenant, Minimum Revenue Required for Trailing Six Months		$ 20,000,000
Oxford Finance LLC and Silicon Valley Bank [Member] | Term Loans B and C [Member]
Debt Covenant, Maximum Number of Days to Draw Loan After Revenue Requirement		60 days
Debt Instrument, Commitment Fee Percentage		2.00%
Oxford Finance LLC [Member]
Class of Warrant or Right, Issued During Period	56,533
Class of Warrant or Right, Issued During Period, Exercise Price	$ 5.97
Silicon Valley Bank [Member]
Class of Warrant or Right, Issued During Period	56,533
Class of Warrant or Right, Issued During Period, Exercise Price	$ 5.97
Silicon Valley Bank [Member] | Term Loan B Funded [Member]
Class of Warrant or Right, Increase to Warrant, Percentage of Loan Divided by Market Value of Common Stock	4.50%

Note 6 - Debt - Long-term Debt

Note 6 - Debt - Long-term Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 30, 2016
Term loan	$ 16,163	$ 16,163
Deferred financing fees	(1,131)	(1,262)
Discount on debt	(1,003)	(1,157)
Total debt	14,029	13,744
Less current portion of long-term debt	1,500
Total long-term debt	$ 12,529	$ 13,744

Note 6 - Debt - Deferred Financ

Note 6 - Debt - Deferred Financing Fees (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2017USD ($)
Deferred financing fees	$ 1,262
Additions during the period	42
Amortization during the period	(173)
Deferred financing fees	$ 1,131

Note 7 - Income Taxes (Details

Note 7 - Income Taxes (Details Textual) - Greatbatch [Member] - Tax Matters Agreement [Member]	Jun. 30, 2017
Equity Issuance Limitations	30.00%
Asset Disposal Limitations	35.00%

Note 8 - Commitments and Cont43

Note 8 - Commitments and Contingencies (Details Textual) $ in Millions	6 Months Ended
	Jun. 30, 2017USD ($)
Purchase Commitment, Remaining Minimum Amount Committed	$ 9.3
Capital Expenditures Yet to Be Incurred	$ 1.6

Note 9 - Earnings (Loss) Per 44

Note 9 - Earnings (Loss) Per Share ("EPS") (Details Textual) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jul. 01, 2016	Jun. 30, 2017	Jul. 01, 2016
Weighted Average Number Diluted Shares Outstanding Adjustment	0	0	0	0

Note 9 - Earnings (Loss) Per 45

Note 9 - Earnings (Loss) Per Share ("EPS") - Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jul. 01, 2016	Jun. 30, 2017	Jul. 01, 2016
Basic net loss per share:
Net loss	$ (11,238)	$ (8,761)	$ (24,360)	$ (15,903)
Weighted average common shares outstanding (in shares)	10,458	10,266	10,396	10,262
Basic net loss per share (in dollars per share)	$ (1.07)	$ (0.85)	$ (2.34)	$ (1.55)
Diluted net loss per share:
Net loss	$ (11,238)	$ (8,761)	$ (24,360)	$ (15,903)
Weighted average common shares outstanding (in shares)	10,458	10,266	10,396	10,262
Dilutive stock options, restricted stock and restricted stock units (in shares)
Weighted average common shares outstanding – assuming dilution (in shares)	10,458	10,266	10,396	10,262
Diluted net loss per share (in dollars per share)	$ (1.07)	$ (0.85)	$ (2.34)	$ (1.55)
Warrant [Member]
Diluted net loss per share:
Outstanding securities and warrants that were not included in the diluted calculation because their effect would be anti-dilutive (in shares)	1,812	1,652	1,812	1,652

Note 10 - Fair Value Measurem46

Note 10 - Fair Value Measurements (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jul. 01, 2016	Jun. 30, 2017	Jul. 01, 2016	Dec. 30, 2016	Mar. 18, 2016
Fair Value Adjustment of Warrants			$ 300,000
Derivative Liability	$ 600,000		600,000
Available-for-sale Securities	30,152,000		30,152,000		$ 55,013,000
Goodwill, Impairment Loss	0	$ 0	0	$ 0
Warrant [Member]
Derivative Liability	$ 600,000		$ 600,000			$ 500,000

Note 10 - Fair Value Measurem47

Note 10 - Fair Value Measurements - Marketable Securities Measured at Fair Value (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 30, 2016
Available-for-sale Securities, Amortized Cost Basis	$ 30,152	$ 55,015
Available-for-sale Securities, Accumulated Gross Unrealized Loss		(2)
Available-for-sale Securities	30,152	55,013
Cash [Member] | Fair Value, Inputs, Level 1 [Member]
Available-for-sale Securities, Amortized Cost Basis	16,665	33,821
Available-for-sale Securities, Accumulated Gross Unrealized Loss
Available-for-sale Securities	16,665	33,821
Federal Home Loan Bank Certificates and Obligations (FHLB) [Member] | Fair Value, Inputs, Level 1 [Member]
Available-for-sale Securities, Amortized Cost Basis	4,495
Available-for-sale Securities, Accumulated Gross Unrealized Loss
Available-for-sale Securities	4,495
US Treasury and Government [Member] | Fair Value, Inputs, Level 1 [Member]
Available-for-sale Securities, Amortized Cost Basis		2,005
Available-for-sale Securities, Accumulated Gross Unrealized Loss
Available-for-sale Securities		2,005
Financial Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Available-for-sale Securities, Amortized Cost Basis	5,993	8,064
Available-for-sale Securities, Accumulated Gross Unrealized Loss		(1)
Available-for-sale Securities	5,993	8,063
Industrial Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Available-for-sale Securities, Amortized Cost Basis	2,999	11,125
Available-for-sale Securities, Accumulated Gross Unrealized Loss		(1)
Available-for-sale Securities	$ 2,999	$ 11,124

Note 10 - Fair Value Measurem48

Note 10 - Fair Value Measurements - Fair Value Assumptions of Warrants (Details) - Warrant [Member]	6 Months Ended
	Jun. 30, 2017
Risk-free interest rate	2.16%
Expected volatility	55.00%
Contractual term (in years) (Year)	10 years
Dividend yield	0.00%

Note 11 - Business Segment, G49

Note 11 - Business Segment, Geographic and Concentration Risk Information (Details Textual)	6 Months Ended
	Jun. 30, 2017
Number of Reportable Segments	2
Number of Reporting Units	2

Note 11 - Business Segment, G50

Note 11 - Business Segment, Geographic and Concentration Risk Information - Product Line Sales (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jul. 01, 2016	Jun. 30, 2017	Jul. 01, 2016
Sales revenue, net	$ 7,223	$ 2,554	$ 12,263	$ 4,616
Algovita [Member]
Sales revenue, net	5,491	569	8,878	984
Neural Interface Components and Systems [Member]
Sales revenue, net	1,174	1,321	2,375	2,457
Development and Engineering Services [Member]
Sales revenue, net	$ 558	$ 664	$ 1,010	$ 1,175

Note 11 - Business Segment, G51

Note 11 - Business Segment, Geographic and Concentration Risk Information - Business Segments Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jul. 01, 2016	Jun. 30, 2017	Jul. 01, 2016
Sales revenue, net	$ 7,223	$ 2,554	$ 12,263	$ 4,616
Segment loss from operations	(10,723)	(8,250)	(23,272)	(15,333)
Unallocated operating expenses	14,407	9,541	29,585	17,631
Unallocated other expense, net	(515)	(511)	(1,088)	(570)
Loss before provision for income taxes	(11,238)	(8,761)	(24,360)	(15,903)
Operating Segments [Member]
Segment loss from operations	(10,723)	(8,250)	(23,272)	(15,333)
Segment Reconciling Items [Member]
Unallocated operating expenses
Nuvectra Segment [Member]
Sales revenue, net	6,049	1,233	9,888	2,159
Nuvectra Segment [Member] | Operating Segments [Member]
Segment loss from operations	(10,813)	(8,316)	(23,418)	(15,217)
NeuroNexus Segment [Member]
Sales revenue, net	1,174	1,321	2,375	2,457
NeuroNexus Segment [Member] | Operating Segments [Member]
Segment loss from operations	$ 90	$ 66	$ 146	$ (116)

Note 11 - Business Segment, G52

Note 11 - Business Segment, Geographic and Concentration Risk Information - Sales by Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jul. 01, 2016	Jun. 30, 2017	Jul. 01, 2016
Sales revenue, net	$ 7,223	$ 2,554	$ 12,263	$ 4,616
UNITED STATES
Sales revenue, net	5,601	1,163	9,371	1,827
SWITZERLAND
Sales revenue, net	586	724	1,059	1,270
GERMANY
Sales revenue, net	523	309	874	865
Rest of World [Member]
Sales revenue, net	$ 513	$ 358	$ 959	$ 654

Note 12 - Related Party Trans53

Note 12 - Related Party Transactions (Details Textual) $ in Millions	Mar. 14, 2016USD ($)
Integer [Member]
Proceeds from Contributions from Parent	$ 75